Drug
Trastuzumab rezetecan clinical trials
Keep track of what changes. Save the trastuzumab rezetecan studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
92 studies that test it; most in 2026 (37)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 6 |
| 2023 | 11 |
| 2024 | 9 |
| 2025 | 26 |
| 2026 | 37 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 30 · Other 62
Jiangsu HengRui Medicine Co., Ltd. (19) · Fudan University (13) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (11) · Henan Cancer Hospital (6) · Tianjin Medical University Cancer Institute and Hospital (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (4) · Tongji Hospital (3) · Sun Yat-sen University (3)
Often tested with
Tested in the same studies.
Adebrelimab (17) · Bevacizumab (7) · Pyrotinib (7) · Trastuzumab (6) · Famitinib (5) · Tizetatug rezetecan (4) · SHR-1701 (4) · Capecitabine (4)
Studies
Open first, then newest update. How each study uses trastuzumab rezetecan is read from its arms, and is right about nine times in ten.
Testing it · 92
- Reverse Triple Negative Immune Resistant Breast CancerRecruitingPhase 2Fudan UniversityNCT05076682Written as SHR-A1811
- The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07203729Written as Trastuzumab Rezetecan
- Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tongji HospitalNCT07865611Written as Trastuzumab Rezetecan
- SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete ResponseNot yet recruitingPhase 2Fudan UniversityNCT07856303Written as SHR-A1811
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT07843303Written as Trastuzumab Rezetecan (SHR-A1811)
- Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung CancerNot yet recruitingPhase 2Ming ChenNCT07836543Written as Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy FailureNot yet recruitingPhase 2Henan Cancer HospitalNCT07817654Written as Trastuzumab Rezetecan+Retlirafusp alfa
- Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07817082Written as SHR- A1811
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002Written as SHR-A1811
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07676162Written as SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and Bevacizumab
- Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07802288Written as Trastuzumab Rezetecan + Retlirafusp alfa + CAPOX
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as SHR-A1811
- A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2Not yet recruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07796763Written as Trastuzumab Rezetecan (SHR-A1811) injection; high dose
- SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast CancerNot yet recruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07787338Written as SHR-A1811
- A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLCNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07778745Written as Trastuzumab rezetecan
- Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07776171Written as Trastuzumab Rezetecan (SHR-A1811)
- First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) AlterationsNot yet recruitingPhase 2Yongsheng WangNCT07699952Written as Trastuzumab Rezetecan
- Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNot yet recruitingPhase 2Fujian Cancer HospitalNCT07766772Written as Trastuzumab Rezetecan
- An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBCNot yet recruitingPhase 3Fudan UniversityNCT07760844Written as SHR- A1811+ eve
- Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUCRecruitingPhase 2Zhiquan HuNCT07741448Written as Trastuzumab Rezetecan
See all 92 studies that test trastuzumab rezetecan →
Given in every arm · 13 — trastuzumab rezetecan is usual care beside what is tested
- Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesRecruitingPhase 2Henan Cancer HospitalNCT07100600Written as Trastuzumab Rezetecan
- A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Shengdi Pharmaceutical Co., LtdNCT07231211Written as SHR-A1811 for injection
- A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07679360Written as Trastuzumab Rezetecan for Injection
- Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast CancerRecruitingPhase 2Beijing GoBroad HospitalNCT06433609Written as SHR-A1811
- Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerRecruitingPhase 4Peking University People's HospitalNCT07600164Written as Trastuzumab Rezetecan
- Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)RecruitingPhase 2Sun Yat-sen UniversityNCT07241793Written as Trastuzumab Rezetecan
- Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain MetastasesRecruitingPhase 2Henan Cancer HospitalNCT05769010Written as SHR-A1811
- Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07466303Written as SHR-A1811
- A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingPhase 1/2Peking University Cancer Hospital & InstituteNCT07177950Written as SHR-A1811
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07102901Written as SHR-A1811 Injection
- SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecruitingPhase 1/2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775Written as SHR-A1811
- Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain MetastasisRecruitingPhase 1/2Fudan UniversityNCT06718933Written as SHR-A1811
- A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer PatientsRecruitingPhase 2Shengjing HospitalNCT05635487Written as SHR-A1811
As the comparator · 2 — what is tested is compared with trastuzumab rezetecan
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Written as Trastuzumab Rezetecan
- An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBCNot yet recruitingPhase 3Fudan UniversityNCT07669610Written as SHR- A1811
Codes
What other systems call trastuzumab rezetecan · ClinicalTrials.gg INT014248
- UNII (FDA) 1000BJC8CRTRASTUZUMAB REZETECANOne source FDA
- NCI Thesaurus C178312Trastuzumab RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1000BJC8CR | TRASTUZUMAB REZETECAN | One source FDA |
| NCI Thesaurus | C178312 | Trastuzumab Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.